Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| LL-37 (Cathelicidin) | PT-141 (Bremelanotide) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 50-100 mcg daily via subcutaneous injection for immune support. | Research indicates 1.75 mg administered via subcutaneous injection approximately 45 minutes before anticipated sexual activity. |
| Timing | Morning administration preferred for immune support. Topical application directly to wound sites. | 45-60 minutes before anticipated sexual activity. Effects last 6-72 hours depending on individual response. |
| Cycle Duration | 4-8 week cycles. Short-term use preferred due to limited long-term safety data. | As-needed basis. Not intended for daily use. |
| Evidence Level | animal_plus_anecdotal | strong_human |
LL-37 is a 37-residue amphipathic helical antimicrobial peptide, the only human cathelicidin, that kills bacteria by forming tetrameric channels that perforate cytoplasmic membranes. Beyond direct antimicrobial activity, it modulates innate immunity through formyl-peptide receptor 2 (FPR2), induces chemotaxis of neutrophils and monocytes, upregulates CXCR4 and IL-8, and neutralizes bacterial endotoxins (LPS). It also promotes wound healing through keratinocyte migration and angiogenesis.
Research indicates 50-100 mcg daily via subcutaneous injection for immune support.
Morning administration preferred for immune support. Topical application directly to wound sites.
4-8 week cycles. Short-term use preferred due to limited long-term safety data.
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin analog that acts as an agonist at MC3R and MC4R melanocortin receptors, with higher affinity for MC4R. It enhances sexual desire by activating presynaptic MC4Rs on neurons in the medial preoptic area (mPOA) of the hypothalamus, increasing dopamine release — an excitatory neurotransmitter for sexual desire. Unlike PDE5 inhibitors, PT-141 works centrally through the CNS rather than peripherally on blood flow, addressing desire rather than just erectile mechanics.
Research indicates 1.75 mg administered via subcutaneous injection approximately 45 minutes before anticipated sexual activity.
45-60 minutes before anticipated sexual activity. Effects last 6-72 hours depending on individual response.
As-needed basis. Not intended for daily use.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →